You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023256018
Dec 2023116017
Jan 20245309
Feb 20245004
Mar 20246800
Apr 20244207
May 20248608
Jun 20244602
Jul 20246807
Aug 202476015
Sep 20244405
Oct 20245208
Nov 20245707
Dec 202462014
Jan 20254406
Feb 20252207
Mar 20250013
Apr 2025106
May 2025007
Jun 2025007
Total11430167